Abstract
Historically treated as monomeric polypeptides, G protein-coupled receptors (GPCRs) have been shown to exist and function as constitutively formed dimers or oligomers. The quaternary structure of GPCRs may modulate ligand binding properties through allosteric mechanisms offering new opportunities for drug design by exploiting multivalency. In this context, multivalent ligands versus bivalent-ligands, possessing two binding motifs connected by a linker, have been investigated and have revealed striking differences in their functional properties compared to their monovalent counterparts. These bi-functional drugs, which are able to activate the two protomers in a dimer simultaneously, emerge as novel and promising drugs for a variety of multi-factorial diseases. In this review, key requirements for the successful design and synthesis of GPCR multivalent ligands composed of pharmacophores and a linker will be discussed. We will then focus on the 5-HT4 receptor (5-HT4R), whose ligands emerged as promising drugs for a variety of central nervous disorders. Upon description of biochemical and biophysical evidences of 5-HT4R dimerization, we will present the multivalent ligand approach, which was assisted by molecular docking experiments on the 5-HT4R dimer model.
Keywords: Bivalent ligands, GPCR oligomers, drug design, 5-HT4 receptors, molecular modeling, organic synthesis, BRET screening.
Current Pharmaceutical Design
Title: Multivalent-Based Drug Design Applied to Serotonin 5-HT4 Receptor Oligomers
Volume: 15 Issue: 6
Author(s): Frank Lezoualc'h, Ralf Jockers and Isabelle Berque-Bestel
Affiliation:
Keywords: Bivalent ligands, GPCR oligomers, drug design, 5-HT4 receptors, molecular modeling, organic synthesis, BRET screening.
Abstract: Historically treated as monomeric polypeptides, G protein-coupled receptors (GPCRs) have been shown to exist and function as constitutively formed dimers or oligomers. The quaternary structure of GPCRs may modulate ligand binding properties through allosteric mechanisms offering new opportunities for drug design by exploiting multivalency. In this context, multivalent ligands versus bivalent-ligands, possessing two binding motifs connected by a linker, have been investigated and have revealed striking differences in their functional properties compared to their monovalent counterparts. These bi-functional drugs, which are able to activate the two protomers in a dimer simultaneously, emerge as novel and promising drugs for a variety of multi-factorial diseases. In this review, key requirements for the successful design and synthesis of GPCR multivalent ligands composed of pharmacophores and a linker will be discussed. We will then focus on the 5-HT4 receptor (5-HT4R), whose ligands emerged as promising drugs for a variety of central nervous disorders. Upon description of biochemical and biophysical evidences of 5-HT4R dimerization, we will present the multivalent ligand approach, which was assisted by molecular docking experiments on the 5-HT4R dimer model.
Export Options
About this article
Cite this article as:
Lezoualc'h Frank, Jockers Ralf and Berque-Bestel Isabelle, Multivalent-Based Drug Design Applied to Serotonin 5-HT4 Receptor Oligomers, Current Pharmaceutical Design 2009; 15 (6) . https://dx.doi.org/10.2174/138161209787315602
DOI https://dx.doi.org/10.2174/138161209787315602 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Electrophysiological Changes in Alzheimer's Disease: A Microarray Based Transcriptomics and Molecular Pathway Analysis Study
CNS & Neurological Disorders - Drug Targets Recent Updates of N-Type Calcium Channel Blockers with Therapeutic Potential for Neuropathic Pain and Stroke
Current Topics in Medicinal Chemistry Gels and Jellies as a Dosage Form for Dysphagia Patients: A Review
Current Drug Therapy Recent Advances in the Development of Anti-Infective Prophylactic and/or Therapeutic Agents Based on Toll-Like Receptor (TLRs)
Recent Patents on Anti-Infective Drug Discovery Agents Complexing Copper as a Therapeutic Strategy for the Treatment of Alzheimers Disease
Current Alzheimer Research Brain Nitric Oxide and Its Dual Role in Neurodegeneration / Neuroprotection: Understanding Molecular Mechanisms to Devise Drug Approaches
Current Medicinal Chemistry Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia
Current Neurovascular Research Potential Lithium and Fluoride Interactions in Studies of Glycogen Synthase Kinase-3
Current Enzyme Inhibition Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Current Cancer Drug Targets State Dissociation, Human Behavior, and Consciousness
Current Topics in Medicinal Chemistry The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry New Approaches for the Selection and Evaluation of Anti-Prion Organic Compounds
Mini-Reviews in Medicinal Chemistry Mesenchymal Stromal Cell Secretome: Immunomodulation, Tissue Repair and Effects on Neurodegenerative Conditions
Current Stem Cell Research & Therapy Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Experimental and Clinical Application of Plasmid DNA in the Field of Central Nervous Diseases
Current Gene Therapy Promises and Challenges of Adult Stem Cells in Cancer Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Isoflurane Facilitates Synaptic NMDA Receptor Endocytosis in Mice Primary Neurons
Current Molecular Medicine Amyloid-beta Induced Neurotoxicity Impairs Cognition and Adult Hippocampal Neurogenesis in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research PET Radiotracers for Molecular Imaging in Dementia
Current Radiopharmaceuticals Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology